Tokio Marine Asset Management Co. Ltd. Buys 128 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 7.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,958 shares of the medical instruments supplier’s stock after acquiring an additional 128 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in West Pharmaceutical Services were worth $689,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of WST. Planned Solutions Inc. acquired a new position in West Pharmaceutical Services during the fourth quarter worth approximately $39,000. Addison Advisors LLC increased its position in West Pharmaceutical Services by 37.9% during the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 39 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new position in West Pharmaceutical Services during the third quarter worth approximately $71,000. Livforsakringsbolaget Skandia Omsesidigt increased its position in West Pharmaceutical Services by 90.0% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 90 shares during the last quarter. Finally, Lindbrook Capital LLC increased its position in West Pharmaceutical Services by 46.0% during the fourth quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock worth $83,000 after buying an additional 74 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Insiders Place Their Bets

In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the sale, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the sale, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric Mark Green sold 64,132 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $359.85, for a total value of $23,077,900.20. Following the completion of the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $55,023,943.80. The disclosure for this sale can be found here. Insiders sold 73,978 shares of company stock worth $26,653,772 over the last three months. Insiders own 0.53% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the topic of a number of recent analyst reports. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. KeyCorp upped their target price on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research report on Tuesday, February 13th. UBS Group decreased their target price on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research report on Friday, February 16th. Finally, Jefferies Financial Group raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their target price for the company from $323.00 to $536.00 in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and an average price target of $435.20.

West Pharmaceutical Services Trading Down 2.1 %

Shares of NYSE:WST opened at $360.43 on Friday. The company has a market capitalization of $26.39 billion, a P/E ratio of 47.55, a P/E/G ratio of 6.27 and a beta of 1.04. West Pharmaceutical Services, Inc. has a 1 year low of $310.42 and a 1 year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.88 and a quick ratio of 2.24. The business’s 50 day simple moving average is $377.63 and its 200 day simple moving average is $364.13.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.29% and a net margin of 19.42%. The business had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. During the same quarter in the prior year, the business posted $1.98 earnings per share. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. On average, research analysts anticipate that West Pharmaceutical Services, Inc. will post 7.65 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.22%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is presently 10.55%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.